Poh's, simple strategy of making old drugs better, hence not...

Poh's, simple strategy of making old drugs better, hence not re-creating the wheel, coupled with a diligent approach to FDA submission encourages me greatly, more so when I read the trials and tribulations faced by others.

Notably QRX, sitting on a $16 million cash, a monthly cash burn rate of $2.2 million and drug that has no precedents with the FDA "The FDA also voiced for the first time that no precedent exists for their review of combination products where two drugs in the same category are comboned") - poor QRX shareholders will have their resubmission by late Q2 - by that stage, funds will have depleted enormously, and they would be going to market for another cap raise, to see them through the approval process.

http://www.asx.com.au/asxpdf/20130124/pdf/42clk8q7fpm12c.pdf

POH is no one trick pony, undertakes a sophisticated approach to the KISS method and is fully funded and diligent.